Prophylaxis, empirical, preemptive therapy in presumed aspergillosis in hematolological patients: which strategy?

被引：0
|
作者：
Maschmeyer, G. [1 ]
机构：
[1] Klinikum Ernst Von Bergmann, Potsdam, Germany
来源：
MYCOSES | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 48 条
  • [21] Which Advanced Heart Failure Therapy Strategy is Optimal for Patients Over 60 Years Old?
    Gernhofer, Y. K.
    Braun, O. O.
    Brambatti, M.
    Bui, Q. M.
    Enciso, J. Silva
    Greenberg, B. H.
    Adler, E.
    Pretorius, V.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S315 - S315
  • [22] Which advanced heart failure therapy strategy is optimal for patients over 60 years old?
    Gernhofer, Yan K.
    Braun, Oscar O.
    Brambatti, Michela
    Bui, Quan M.
    Silva Enciso, Jorge
    Greenberg, Barry H.
    Adler, Eric
    Pretorius, Victor
    JOURNAL OF CARDIOVASCULAR SURGERY, 2019, 60 (02): : 251 - 258
  • [23] Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy
    Carualho, Fabiana Rabe
    Juliboni Cosendey, Rachel Ingrid
    Souza, Cintia Fernandes
    Medeiros, Thalia
    Menezes, Paulo Alexandre
    Silva, Andrea Alice
    Almeida, Jorge Reis
    Lugon, Jocemir Ronaldo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2017, 21 (01): : 51 - 56
  • [24] SECONDARY ANTIFUNGAL PROPHYLAXIS BASED ON RESPONSE TO INITIAL ANTIFUNGAL THERAPY FOR PATIENTS WITH A HISTORY OF INVASIVE PULMONARY ASPERGILLOSIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
    Liu, Q.
    Lin, R.
    Sun, J.
    Xiao, Y.
    Nie, D.
    Zhang, Y.
    Huang, F.
    Fan, Z.
    Zhou, H.
    Jiang, Q.
    Zhang, F.
    Zhai, X.
    Xu, D.
    Wei, Y.
    Song, J.
    Li, Y.
    Feng, R.
    HAEMATOLOGICA, 2013, 98 : 381 - 381
  • [25] Prospective Comparison of Cytomegalovirus-Specific Immunity in Donor Seropositive/Recipient Seronegative Liver Transplant Patients Receiving Preemptive Therapy or Antiviral Prophylaxis.
    Limaye, Ajit P.
    Singh, Nina
    Chatterton-Kirchmeier, Sam
    Thuntarug, Mujalin
    Stevens-Ayers, Terry
    Boeckh, Michael
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 249 - 249
  • [26] Which is the most cost-effective combination therapy strategy for naive patients with chronic hepatitis C?
    Buti, M
    Casado, MA
    Fosbrook, L
    Esteban, R
    JOURNAL OF HEPATOLOGY, 2001, 34 : 162 - 162
  • [27] Which combination therapy strategy for "naive" patients with chronic hepatitis C is the most cost-effective?.
    Buti, M
    Casado, MA
    Medina, M
    Fosbrook, L
    Esteban, R
    HEPATOLOGY, 2001, 34 (04) : 426A - 426A
  • [28] Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy
    Mikolajewska, Agata
    Schwartz, Stefan
    Ruhnke, Markus
    MYCOSES, 2012, 55 (01) : 2 - 16
  • [29] Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy
    Bramlage, Peter
    Bluhmki, Tobias
    Rathmann, Wolfgang
    Kaltheuner, Matthias
    Beyersmann, Jan
    Danne, Thomas
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 : 127 - 135
  • [30] Which strategy of immunoablative therapy with autologous stem cell transplantation (ASCT) is preferable in multiple sclerosis (MS) patients?
    Shevchenko, Yury L.
    Novik, Andrei A.
    Kuznetcov, Alexey N.
    Afanasiev, Boris A.
    Lisukov, Lgora.
    Rykavicin, Oleg A.
    Myasnikov, Alexandr A.
    Ionova, Tatyana I.
    Melnichenko, Vladimir J.
    Fedorenko, Denis A.
    Kishtovich, Anton V.
    Ivanov, Roman A.
    Gorodokin, Gary J.
    BLOOD, 2007, 110 (11) : 354B - 354B
12345